Search results for "SCALES"

showing 10 items of 543 documents

WAIS-IV Performance in Patients With Schizophrenia.

2019

Wechsler Adult Intelligence Scale (WAIS) is one of the most widely used instruments to measure cognitive functioning. The aims of this study were 1) to obtain the cognitive profile of Spanish patients with schizophrenia on the WAIS-IV; 2) to compare their profile to the profile of a healthy control group; and 3) to compare the cognitive profile of patients with schizophrenia to the performance observed in two separate previous studies in Canada and China. A sample of 99 outpatients and 99 healthy control participants, matched on age, sex, and educational level, were measured using the WAIS-IV, including 10 core subtests, 4 indices, and 2 general intelligence scores, to obtain their cognitiv…

AdultMalebehavioral disciplines and activities03 medical and health sciences0302 clinical medicineHealthy controlmedicineHumansVerbal comprehensionIn patientCognitive DysfunctionCognitive skillCognitive impairmentWechsler ScalesWechsler Adult Intelligence ScaleCognitionMiddle Agedmedicine.disease030227 psychiatryPsychiatry and Mental healthSchizophreniaSchizophreniaFemalePsychology030217 neurology & neurosurgeryClinical psychologyThe Journal of nervous and mental disease
researchProduct

Hippocampal subfields predict positive symptoms in schizophrenia : First evidence from brain morphometry

2012

Alterations of hippocampal anatomy have been reported consistently in schizophrenia. Within the present study, we used FreeSurfer to determine hippocampal subfield volumes in 21 schizophrenic patients. A negative correlation between PANSS-positive symptom score and bilateral hippocampal subfield CA2/3 as well as CA1 volume was found on high-resolution magnetic resonance images. Our observation opens the gate for advanced investigation of the commonly reported hippocampal abnormalities in schizophrenia in terms of specific subfields.

AdultMalegenetic structureshippocampusFreeSurferHippocampusHippocampal formationCA1Cellular and Molecular NeurosciencemedicineImage Processing Computer-AssistedHumansddc:610Biological PsychiatryvolumetryPsychiatric Status Rating Scalesmedicine.diagnostic_testBrain morphometryMagnetic resonance imagingOrgan Sizemedicine.diseaseMagnetic Resonance ImagingJschizophreniaPsychiatry and Mental healthnervous systemCA2/3SchizophreniaPsychiatric status rating scalesOriginal ArticleFemaleNegative correlationPsychologyNeuroscienceSymptom score
researchProduct

Nonlinear analysis of sleep EEG data in schizophrenia: calculation of the principal Lyapunov exponent

1995

The generating mechanism of the electroencephalogram (EEG) points to the hypothesis that EEG signals derive from a nonlinear dynamic system. Hence, the unpredictability of the EEG might be considered as a phenomenon exhibiting its chaotic character. The essential property of chaotic dynamics is the so-called sensitive dependence on initial conditions. This property can be quantified by calculating the system's first positive Lyapunov exponent, L1. We calculated L1 for sleep EEG segments of 13 schizophrenic patients and 13 control subjects that corresponded to sleep stages I, II, III, IV and REM (rapid eye movement), as defined by Rechtschaffen and Kales, for the lead positions Cz and Pz. Du…

AdultMalemedia_common.quotation_subjectChaoticPolysomnographyLyapunov exponentElectroencephalographyDevelopmental psychologysymbols.namesakemental disordersmedicineHumansBiological Psychiatrymedia_commonPsychiatric Status Rating ScalesSleep Stagesmedicine.diagnostic_testMathematical analysisEye movementElectroencephalographyPsychiatry and Mental healthNonlinear systemSchizophreniasymbolsFemaleSchizophrenic PsychologySleepPsychologypsychological phenomena and processesVigilance (psychology)Psychiatry Research
researchProduct

A double-blind study comparing paroxetine and maprotiline in depressed outpatients.

1997

A double-blind multicenter randomized parallel group study comparing paroxetine and maprotiline was carried out in a total of 544 outpatients. Included were patients with varying degrees of severity of depressive symptoms who fulfilled modified RDC criteria for either Minor or Major Depression and showed a HAMD-17 score of > or = 13. No concomitant benzodiazepine treatment was allowed. Duration of treatment was 6 weeks, after an initial wash-out period. Doses were fixed during the first 3 weeks of treatment, patients receiving either 20 mg paroxetine or 100 mg maprotiline daily. An option for dose escalation was provided for insufficient responders after 3 weeks. The weekly assessments comp…

AdultMalemedicine.drug_classDouble-Blind MethodAnticholinergicAmbulatory CareMedicineHumansPharmacology (medical)Adverse effectMaprotilinePsychiatric Status Rating ScalesBenzodiazepineDepressive Disorderbusiness.industryGeneral MedicineParoxetinePsychiatry and Mental healthParoxetineMaprotilineConcomitantAnesthesiaAntidepressantAntidepressive Agents Second-GenerationFemalebusinessReuptake inhibitormedicine.drugPharmacopsychiatry
researchProduct

Online Self-Help as an Add-On to Inpatient Psychotherapy: Efficacy of a New Blended Treatment Approach.

2017

<b><i>Background:</i></b> Depression is one of the most frequent and costly mental disorders. While there is increasing evidence for the efficacy of online self-help to improve depression or prevent relapse, there is little evidence in blended care settings, especially combined with inpatient face-to-face psychotherapy. Therefore, we evaluated whether an evidence-based online self-help program improves the efficacy of inpatient psychotherapy. <b><i>Methods:</i></b> A total of 229 depressed patients were randomly allocated either to an online self-help program (intervention group [IG]; Deprexis) or an active control group (CG; weekly online inf…

AdultMalemedicine.medical_specialty020205 medical informaticsDepression Efficacy Inpatient treatment Internet-based treatment Psychosomatic medicine Psychotherapy Randomized controlled trialDysfunctional family02 engineering and technologylaw.invention03 medical and health sciencesDepression Wirksamkeit stationäre Behandlung internetbasierte Behandlung Psychosomatische Medizin Psychotherapie randomisierte kontrollierte Studie0302 clinical medicineQuality of lifeRandomized controlled triallawIntervention (counseling)0202 electrical engineering electronic engineering information engineeringmedicineHumansddc:610PsychiatryApplied PsychologyDepression (differential diagnoses)Psychiatric Status Rating ScalesPsychodynamic psychotherapyDepressive DisorderInpatientsInternetbusiness.industryPsychosomatic medicineGeneral MedicineMiddle Aged030227 psychiatrySelf CarePsychiatry and Mental healthClinical PsychologyTreatment OutcomeTherapy Computer-AssistedAnxietyFemalemedicine.symptombusinessPsychotherapy PsychodynamicPsychotherapy and psychosomatics
researchProduct

Adherence predictors in an Internet-based Intervention program for depression

2017

Internet-delivered psychotherapy has been demonstrated to be effective in the treatment of depression. Nevertheless, the study of the adherence in this type of the treatment reported divergent results. The main objective of this study is to analyze predictors of adherence in a primary care Internet-based intervention for depression in Spain. A multi-center, three arm, parallel, randomized controlled trial was conducted with 194 depressive patients, who were allocated in self-guided or supported-guided intervention. Sociodemographic and clinical characteristics were gathered using a case report form. The Mini international neuropsychiatric interview diagnoses major depression. Beck Depressio…

AdultMalemedicine.medical_specialtyAdolescent020205 medical informaticsPsychological intervention02 engineering and technologylaw.inventionprimary careYoung Adult03 medical and health sciences0302 clinical medicineRandomized controlled trialQuality of lifelawIntervention (counseling)0202 electrical engineering electronic engineering information engineeringHumansMedicineadherencePsychiatryCase report formDepression (differential diagnoses)AgedMini-international neuropsychiatric interviewPsychiatric Status Rating ScalesDepressive Disorder MajorInternetPrimary Health Carebusiness.industryBeck Depression InventoryMiddle AgedInternet-based intervention030227 psychiatryPsychotherapyClinical PsychologyTherapy Computer-AssisteddepressionQuality of LifePatient ComplianceFemalebusinessClinical psychologyCognitive Behaviour Therapy
researchProduct

Virtual reality exposure and imaginal exposure in the treatment of fear of flying: a pilot study

2013

Fear of flying (FF) is an impairing psychological disorder that is extremely common in developed countries. The most effective treatment for this particular type of phobia is exposure therapy. However, there are few studies comparing imaginal exposure (IE) and virtual reality (VR) exposure for the treatment of FF. The present study compared the effectiveness of these two approaches using two manualized interventions based on the exposure technique. Patients with FF ( N = 15) were randomly assigned to either VR ( n = 7) or IE therapy ( n = 8), consisting of a total of eight sessions: two assessment sessions (pre-treatment and after the real flight) and six exposure therapy sessions, which w…

AdultMalemedicine.medical_specialtyAdolescentAircraftmedicine.medical_treatmentExposure therapyPsychological interventionImplosive TherapyPilot ProjectsVirtual realityVirtual realityVirtual Reality Exposure TherapyFear of flyingArts and Humanities (miscellaneous)Fear of flyingImaginal exposureDevelopmental and Educational PsychologymedicinePresenceEffective treatmentHumansPsychiatryAgedPsychiatric Status Rating ScalesVirtual Reality Exposure TherapyMiddle Agedmedicine.diseaseClinical PsychologyPhobic DisordersImaginal capabilityPhysical therapyAnxietyImplosive TherapyFemalemedicine.symptomPsychology
researchProduct

Risperidone Versus Haloperidol and Amitriptyline in the Treatment of Patients With a Combined Psychotic and Depressive Syndrome

1998

In a multicenter, double-blind, parallel group trial, the efficacy of risperidone (RIS) was compared with a combination of haloperidol and amitriptyline (HAL/AMI) over 6 weeks in patients with coexisting psychotic and depressive symptoms with either a schizoaffective disorder, depressive type, a major depression with psychotic features, or a nonresidual schizophrenia with major depressive symptoms according to DSM-III-R criteria. A total of 123 patients (62 RIS; 61 HAL/AMI) were included; the mean daily dosage at endpoint was 6.9 mg RIS versus 9 mg HAL combined with 180 mg AMI. Efficacy results for those 98 patients (47 RIS; 51 HAL/AMI) who completed at least 3 weeks of double-blind treatme…

AdultMalemedicine.medical_specialtyAdolescentAmitriptylineSchizoaffective disorderAntidepressive Agents Tricycliclaw.inventionDouble-Blind MethodExtrapyramidal symptomsRandomized controlled triallawInternal medicineBrief Psychiatric Rating ScalemedicineHaloperidolHumansPharmacology (medical)AmitriptylinePsychiatryAgedPsychiatric Status Rating ScalesDepressive DisorderRisperidoneMiddle AgedRisperidonemedicine.diseasePsychiatry and Mental healthPsychotic DisordersSchizophreniaHaloperidolFemalemedicine.symptomPsychologyAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Requestioning depression in patients with cancer: Contribution of somatic and affective symptoms to Beck's Depression Inventory

2007

Background: Depressive symptoms are a major complaint reported by cancer patients. Somatic and affective symptoms can contribute to depression. Patients and methods: We investigated the prevalence of somatic and affective depressive symptoms with the Beck Depression Inventory (BDI) in 213 hospitalized cancer patients prior to the start of chemotherapy. Results: Seventeen of 213 patients (8%) were screened positive for major depression; 40 (19%) had mild to moderate depressive symptoms. The corresponding figures for somatic and affective symptoms were 33.3% and 2.8% in the patients with major depression and 23.0% and 8.0% in those with mild to moderate depressive symptoms. Female patients, p…

AdultMalemedicine.medical_specialtyAdolescentComorbidityRisk AssessmentStatistics NonparametricHospitals UniversityAge DistributionQuality of lifeGermanyNeoplasmsSickness Impact ProfileSurveys and QuestionnairesInternal medicineAdaptation PsychologicalInterview PsychologicalPrevalencemedicineHumansSex DistributionPsychiatryDepression (differential diagnoses)AgedProbabilityPsychiatric Status Rating ScalesDepressive Disorderbusiness.industryCase-control studyBeck Depression InventoryCancerHematologyMiddle Agedmedicine.diseaseComorbidityChemotherapy regimenCausalityOncologyCase-Control StudiesQuality of LifeMajor depressive disorderFemalebusinessStress PsychologicalFollow-Up StudiesAnnals of Oncology
researchProduct

Dose-Related Effects of Amisulpride on Five Dimensions of Psychopathology in Patients With Acute Exacerbation of Schizophrenia

2002

The present analysis investigated symptom-specific dose-response relationships of the atypical antipsychotic amisulpride (AMI) in schizophrenic patients. The effects of different AMI doses on five different symptom dimensions of the Brief Psychiatric Rating Scale (BPRS) were analyzed. Results on global efficacy and safety parameters have been previously published. Four AMI doses (100 mg/day [AMI100], 400 mg/day [AMI400], 800 mg/day [AMI800], 1200 mg/day) were compared with 16 mg haloperidol (HAL16) in a multicenter, double-blind, randomized, parallel-group, 4-week trial. A total of 319 patients with acute exacerbation of schizophrenia (DSM-III-R) were included. AMI100 was compared with the …

AdultMalemedicine.medical_specialtyAdolescentExacerbationmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticInternal medicineBrief Psychiatric Rating ScalemedicineHaloperidolHumansPharmacology (medical)AmisulpridePsychiatryAntipsychoticPsychiatric Status Rating ScalesDose-Response Relationship DrugDopamine antagonistMiddle AgedPsychiatry and Mental healthTreatment OutcomeSchizophreniaHaloperidolAnxietyFemaleSchizophrenic PsychologyAmisulprideSulpiridemedicine.symptomPsychologyAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct